Merkel Cell Carcinoma Treatment Market

Merkel Cell Carcinoma Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment; 2017 - 2027

  • Ongoing
  • August 2020
  • REP-GB-4408
Merkel Cell Carcinoma Treatment Market

  • US$5,000
  • US$7,500
  • US$10,000

This Merkel Cell Carcinoma Treatment market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Merkel Cell Carcinoma Treatment market.

Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs most often on sun-exposed areas of the skin. A delicate resistant background likewise expands the danger of creating MCC. An expected 2,500 new instances of MCC are analyzed in the EU consistently. The ailment has poor guess with under 20% of patients surviving longer than five years. At the point when not appropriately treated, the ailment can bring about irreversible disfigurement or long haul practical inability. Merkel Cell Carcinoma treatment stays uncommon, however there have been increments in both occurrence and the quantity of endemic territories over the most recent 15 years. The U.S. FDA granted approval to Bavencio (avelumab) drug for treatment of adult patients, pediatric patients 12 years and older. These type of cancer growths are believed to be confined to the skin in view of imaging tests and other physical exams. Once MCC has been analyzed, a sentinel lymph biopsy (SLNB) is normally done prior to check whether little measures of cancer cells have achieved the nodes. Additionally, imaging tests like CT, MRI, or PET/CT scans are also done at the same duration. Treatment choices may incorporate surgery, radiation treatment, chemotherapy, immunotherapy, or some mix of these. Additionally, one of the more up to date immunotherapy medications, for example, pembrolizumab (Keytruda) or avelumab (Bavencio) may be another alternative. In moderately low-risk exposure to MCC tumors, surgery alone can be adequate. In different cases, surgery may not be conceivable and a MCC authority may prescribe radiation treatment or another type of treatment. Contingent upon the general patient wellbeing and the location and size of the MCC, more than one treatment alternative might be utilized.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Merkel Cell Carcinoma Treatment Market: Drivers and Restraints

Growing incidence of Merkel Cell Carcinomas is expected to increase demand for immunotherapy drugs and surgeries. Newly manufactured drugs such as avelumab and pembrolizumab in combination with different therapeutic methods are in line with a greater extent. These prevailing and targeted anti-cancer agents has inveterate selective annihilation of cancerous cells while sparing healthy cells/tissues throughout early and late stage clinical trials. The European Commission approved the first biosimilar AMGEVITA from Amgen pharmaceutical company. It was also approved in the U.S. by the FDA in September 2016. The development is basically determined by expanded prevalence. New companies in the pharmaceutical industry have indicated expanded competence and safety profiles along with lessening the chances of cancer. The MCC treatment market likewise has majorly two different procedures of treatment, which are via several combination therapies and surgery. Temporary rules now suggest the utilization of drugs, generally consolidated with surgery, for the treatment of merkel cell carcinoma. Effective treatment will abbreviate the course of the sickness and limit distortion. Skilled surgery, expert nursing care, and therapeutic physiotherapy are regularly required to accomplish great results. Yet, the remedial action of such events still rests an undiscovered area of research and development for pharmaceutical & healthcare organizations to carry innovative medications and advanced treatment into the merkel cell carcinoma treatment market. However nonappearance of conclusive treatment, adverse reactions, restricted adequacy of the medications and high cost of surgery accessible in the market and reliance in manifestation based treatment in a few cases is required to hamper treatment growth & development of the overall merkel cell carcinoma treatment market over the forecast period.

Merkel Cell Carcinoma Treatment Market: Overview

Every year there are roughly 1,500 new instances of MCC analyzed in the U.S. and 2,500 new cases analyzed in the European region. The acknowledged current treatment for merkel cell carcinoma is typically surgery. Verifiably, the findings of treatment for MCC has been challenging. This is because of the low attention to the condition and its comparable appearance to other skin conditions, for example, favorable benign cysts or lesions, which can defer a suitable treatment. MCC has an altogether higher death rate than the all the more generally known form of skin cancer, melanoma (33% vs. 15%, within five years of infection for all phases of the infection). In more than 33% of patients, MCC already have an impact on a nearby lymph or different parts of the body by the time of diagnosis, implying that the malignancy has progressed to stage III or IV. The current financial and social weight forced by merkel cell carcinoma is colossal. The global market for merkel cell carcinoma treatment is expected to witness firm growth owing to increasing incidence rate of the skin cancer cases worldwide coupled with new treatment approach.

Merkel Cell Carcinoma Treatment Market: Region – wise Outlook

Globally the merkel cell carcinoma treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East and Africa (MEA). North America and Western Europe are expected to be the leading markets in the global merkel cell carcinoma treatment market. Rising treatment options among the middle age population, prescription rates and the maturing worldwide population are additionally considered vital drivers for this market. Public awareness via hospitals, drug manufacturers, medical campaigns and simply available diagnostic tests are relied upon to lift interest for merkel cell carcinoma treatment items in these areas. Japan and APEJ are relied upon to take after next as far as interest for the treatment of merkel cell carcinoma treatment advertise. Eastern Europe, Latin America and MEA markets are likewise anticipated that would witness normal development over the forecast period. Nonattendance of populace based reviews in creating nations is a noteworthy test in appraisal of skin related contaminations in these nations.

Merkel Cell Carcinoma treatment Market: Participants

  • Merck
  • Amgen Inc
  • Apcure SAS
  • BeiGene Ltd
  • Immune Design Corp
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • OncoSec Medical Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2012 - 2016
  • Market Size & Forecast 2017 to 2027
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
  • Aircraft Refurbishing Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Merkel Cell Carcinoma Treatment Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Merkel Cell Carcinoma Treatment Market: Segmentation

By Treatment

  • Chemotherapy
  • Cisplatin
  • Carboplatin
  • Etoposide
  • Topotecan
  • Immunotherapy
  • Avelumab
  • Pembrolizumab
  • Combination Therapies
  • Others

By End Users

  • Hospitals
  • Specialty Cancer Research Institutes and Treatment Centers
  • Ambulatory Surgical Centres
  • Others

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Merkel Cell Carcinoma Treatment Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Merkel Cell Carcinoma Treatment Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Akshay Godge

Akshay Godge

Client Partner - Global Business Development

Our Clients

Request Sample Request customization Request Methodology